These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36735074)

  • 1. Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: a real-life, retrospective study on behalf of the "RTL" (regional Tuscan lymphoma network).
    Cencini E; Romano I; Ghio F; Camerini C; Bertaggia I; Giachetti R; Mannelli L; Pirrotta MT; Navei GL; Ciceri M; Cervetti G; Sant'Antonio E; Simonetti F; Birtolo S; Puccini B; Bocchia M; Fabbri A
    Ann Hematol; 2023 Apr; 102(4):841-849. PubMed ID: 36735074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a real-life, retrospective, multicenter trial on behalf of the "RTL" (regional Tuscan lymphoma network).
    Cencini E; Mecacci B; Morelli F; Ghio F; Romano I; Birtolo S; Simonetti F; Zoi V; Moretti S; Sant'Antonio E; Cuccaro A; Santini S; Kovalchuk S; Galimberti S; Bocchia M; Fabbri A
    Am J Blood Res; 2021; 11(4):373-383. PubMed ID: 34540345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate
    Trotman J; Buske C; Tedeschi A; Matous JV; MacDonald D; Tam CS; Tournilhac O; Ma S; Treon SP; Oriol A; Ping J; Briso EM; Arango-Hisijara I; Dimopoulos MA
    Clin Cancer Res; 2021 Nov; 27(21):5793-5800. PubMed ID: 34380643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The efficacy and safety of ibrutinib in the treatment of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia].
    Huang YS; Xiong WJ; Yuan JJ; Yu Y; Li YX; Yan YT; Wang TY; Lyu R; Liu W; An G; Zhao YZ; Zou DH; Qiu LG; Yi SH
    Zhonghua Xue Ye Xue Za Zhi; 2024 Aug; 45(8):755-760. PubMed ID: 39307722
    [No Abstract]   [Full Text] [Related]  

  • 5. Ibrutinib Efficacy, Safety, and Pharmacokinetics in Chinese Patients with Relapsed or Refractory Waldenström's Macroglobulinemia: A Multicenter, Single-Arm, Phase 4 Study.
    Yi S; Cai Z; Hu Y; He A; Gao S; Li Q; Sha L; Zhang N; Ren Y; Gai X; Yang X; Qin R; Qiu L
    Adv Ther; 2024 Feb; 41(2):672-685. PubMed ID: 38079089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.
    Treon SP; Gustine J; Meid K; Yang G; Xu L; Liu X; Demos M; Kofides A; Tsakmaklis N; Chen JG; Munshi M; Chan G; Dubeau T; Raje N; Yee A; O'Donnell E; Hunter ZR; Castillo JJ
    J Clin Oncol; 2018 Sep; 36(27):2755-2761. PubMed ID: 30044692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.
    Treon SP; Meid K; Gustine J; Yang G; Xu L; Liu X; Patterson CJ; Hunter ZR; Branagan AR; Laubach JP; Ghobrial IM; Palomba ML; Advani R; Castillo JJ
    J Clin Oncol; 2021 Feb; 39(6):565-575. PubMed ID: 32931398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.
    Abeykoon JP; Zanwar S; Ansell SM; Gertz MA; Kumar S; Manske M; Novak AJ; King R; Greipp P; Go R; Inwards D; Muchtar E; Habermann T; Witzig TE; Thompson CA; Dingli D; Lacy MQ; Leung N; Dispenzieri A; Gonsalves W; Warsame R; Kyle RA; Rajkumar V; Parikh SA; Kapoor P
    Br J Haematol; 2020 Feb; 188(3):394-403. PubMed ID: 31468508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
    Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT; Shustik C; García-Sanz R; Cornell RF; de Larrea CF; Castillo JJ; Granell M; Kyrtsonis MC; Leblond V; Symeonidis A; Kastritis E; Singh P; Li J; Graef T; Bilotti E; Treon S; Buske C;
    Lancet Oncol; 2017 Feb; 18(2):241-250. PubMed ID: 27956157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
    Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; Sanz RG; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyz J; Fernández de Larrea C; Belada D; Libby E; Matous JV; Motta M; Siddiqi T; Tani M; Trneny M; Minnema MC; Buske C; Leblond V; Trotman J; Chan WY; Schneider J; Ro S; Cohen A; Huang J; Dimopoulos M
    Blood; 2020 Oct; 136(18):2038-2050. PubMed ID: 32731259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up.
    Trotman J; Opat S; Gottlieb D; Simpson D; Marlton P; Cull G; Munoz J; Tedeschi A; Roberts AW; Seymour JF; Atwal SK; Yu Y; Novotny W; Holmgren E; Tan Z; Hilger JD; Huang J; Tam CS
    Blood; 2020 Oct; 136(18):2027-2037. PubMed ID: 32698195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
    Buske C; Tedeschi A; Trotman J; García-Sanz R; MacDonald D; Leblond V; Mahe B; Herbaux C; Matous JV; Tam CS; Heffner LT; Varettoni M; Palomba ML; Shustik C; Kastritis E; Treon SP; Ping J; Hauns B; Arango-Hisijara I; Dimopoulos MA
    J Clin Oncol; 2022 Jan; 40(1):52-62. PubMed ID: 34606378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia.
    An G; Zhou D; Cheng S; Zhou K; Li J; Zhou J; Xie L; Jin J; Zhong L; Yan L; Guo H; Du C; Zhong J; Yu Y; Wu B; Qiu L
    Clin Cancer Res; 2021 Oct; 27(20):5492-5501. PubMed ID: 34253577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful and safe response to ibrutinib alone in treating relapsed Waldenström macrogobulinemia and related acquired von Willebrand syndrome: an option to consider.
    Butelet A; Poulain S; Jeanpierre E; Srour M; Nudel M; Chauvet P; Bauters A; Susen S; Dupont A; de Charette M
    Leuk Lymphoma; 2022 Dec; 63(13):3100-3104. PubMed ID: 36528585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.
    Gustine JN; Meid K; Dubeau T; Severns P; Hunter ZR; Guang Y; Xu L; Treon SP; Castillo JJ
    Am J Hematol; 2018 Aug; 93(4):511-517. PubMed ID: 29280186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia.
    Castillo JJ; Meid K; Gustine JN; Leventoff C; White T; Flynn CA; Sarosiek S; Demos MG; Guerrera ML; Kofides A; Liu X; Munshi M; Tsakmaklis N; Xu L; Yang G; Branagan AR; O'Donnell E; Raje N; Yee AJ; Patterson CJ; Hunter ZR; Treon SP
    Leukemia; 2022 Feb; 36(2):532-539. PubMed ID: 34531537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.
    Dimopoulos M; Sanz RG; Lee HP; Trneny M; Varettoni M; Opat S; D'Sa S; Owen RG; Cull G; Mulligan S; Czyz J; Castillo JJ; Motta M; Siddiqi T; Gironella Mesa M; Granell Gorrochategui M; Talaulikar D; Zinzani PL; Askari E; Grosicki S; Oriol A; Rule S; Kloczko J; Tedeschi A; Buske C; Leblond V; Trotman J; Chan WY; Michel J; Schneider J; Tan Z; Cohen A; Huang J; Tam CS
    Blood Adv; 2020 Dec; 4(23):6009-6018. PubMed ID: 33284944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia.
    Castillo JJ; Branagan AR; Sermer D; Flynn CA; Meid K; Little M; Stockman K; White T; Canning A; Guerrera ML; Kofides A; Liu S; Liu X; Richardson K; Tsakmaklis N; Patterson CJ; Hunter ZR; Treon SP; Sarosiek S
    Blood; 2024 Feb; 143(7):582-591. PubMed ID: 37971194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
    Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
    JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.
    Dimopoulos MA; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; Garcia-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyz J; Fernández de Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Chan WY; Schneider J; Allewelt H; Patel S; Cohen A; Tam CS
    J Clin Oncol; 2023 Nov; 41(33):5099-5106. PubMed ID: 37478390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.